BACKGROUND AND OBJECTIVE: Carbamazepine is a potent inducer of drug metabolizing enzymes, which results in a number of clinically significant drug-drug interactions. Deinduction occurs when long-term carbamazepine therapy is discontinued. The goal of this study was to develop a population pharmacokinetic model to describe the time course of carbamazepine deinduction. PATIENTS AND METHODS: Stable-labelled carbamazepine was administered intravenously on three occasions during the deinduction period to 15 patients with epilepsy for whom carbamazepine therapy was being discontinued. Data were analysed using a nonlinear mixed-effects model (NONMEM). An enzyme turnover model consisting of a one-compartment model linked with a hypothetical enzyme compartment was applied to characterize the time course of carbamazepine deinduction. Model evaluation was performed using the bootstrap approach and a visual predictive check. RESULTS: In the final model, the deinduction process was accomplished by decreasing the rate of enzyme synthesis, resulting in a decrease in the relative amount of enzymes. The estimated rate constant for enzyme degradation was 0.00805 h-1, corresponding to a half-life of the combined enzymes of 86.1 hours (3.6 days). CONCLUSION: An enzyme turnover model adequately characterized the experimental data. Based on the predicted enzyme half-life from the final model, the deinduction process should be completed within 2 weeks after carbamazepine therapy is terminated.
BACKGROUND AND OBJECTIVE:Carbamazepine is a potent inducer of drug metabolizing enzymes, which results in a number of clinically significant drug-drug interactions. Deinduction occurs when long-term carbamazepine therapy is discontinued. The goal of this study was to develop a population pharmacokinetic model to describe the time course of carbamazepine deinduction. PATIENTS AND METHODS: Stable-labelled carbamazepine was administered intravenously on three occasions during the deinduction period to 15 patients with epilepsy for whom carbamazepine therapy was being discontinued. Data were analysed using a nonlinear mixed-effects model (NONMEM). An enzyme turnover model consisting of a one-compartment model linked with a hypothetical enzyme compartment was applied to characterize the time course of carbamazepine deinduction. Model evaluation was performed using the bootstrap approach and a visual predictive check. RESULTS: In the final model, the deinduction process was accomplished by decreasing the rate of enzyme synthesis, resulting in a decrease in the relative amount of enzymes. The estimated rate constant for enzyme degradation was 0.00805 h-1, corresponding to a half-life of the combined enzymes of 86.1 hours (3.6 days). CONCLUSION: An enzyme turnover model adequately characterized the experimental data. Based on the predicted enzyme half-life from the final model, the deinduction process should be completed within 2 weeks after carbamazepine therapy is terminated.
Authors: M Hassan; U S Svensson; P Ljungman; B Björkstrand; H Olsson; M Bielenstein; M Abdel-Rehim; C Nilsson; M Johansson; M O Karlsson Journal: Br J Clin Pharmacol Date: 1999-11 Impact factor: 4.335
Authors: T Kerbusch; A D Huitema; J Ouwerkerk; H J Keizer; R A Mathôt; J H Schellens; J H Beijnen Journal: Br J Clin Pharmacol Date: 2000-06 Impact factor: 4.335
Authors: Lanyan Fang; Nicholas H G Holford; George Hinkle; Xianhua Cao; Jim J Xiao; Mark Bloomston; Seth Gibbs; Osama Habib Al Saif; James T Dalton; Kenneth K Chan; Jeffery Schlom; Edward W Martin; Duxin Sun Journal: J Clin Pharmacol Date: 2007-02 Impact factor: 3.126
Authors: Baralee Punyawudho; Eugene R Ramsay; Richard C Brundage; Flavia M Macias; Joseph F Collins; Angela K Birnbaum Journal: Ther Drug Monit Date: 2012-04 Impact factor: 3.681
Authors: Jeannine M Conway; Angela K Birnbaum; Ilo E Leppik; Page B Pennell; James R White; John O Rarick; Rory P Remmel Journal: Seizure Date: 2014-01-31 Impact factor: 3.184